Brand trends: Vascepa showed a strong recovery with unit growth of 23% and a positive contribution to adjusted EBITDA for the first time, while Clozaril performance stabilized in the U.S. but faces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results